发明名称 BETA3 ADRENERGIC AGONISTS
摘要 <p>The present invention relates to a beta3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.</p>
申请公布号 IL152528(D0) 申请公布日期 2003.05.29
申请号 IL20010152528 申请日期 2001.07.09
申请人 ELI LILLY AND COMPANY 发明人
分类号 A61K31/341;A61K31/381;A61K31/42;A61K31/421;A61K31/425;A61K31/4436;A61K31/4439;A61K31/4545;A61K31/496;A61K31/506;A61K31/5377;A61P3/04;A61P3/10;A61P43/00;C07D207/32;C07D207/333;C07D213/30;C07D213/82;C07D213/84;C07D231/12;C07D261/08;C07D263/32;C07D275/02;C07D277/24;C07D303/22;C07D307/42;C07D307/58;C07D333/16;C07D401/12;C07D403/12;C07D405/12;C07D407/12;C07D409/12;C07D409/14;C07D413/12;C07D417/12;(IPC1-7):C07D 主分类号 A61K31/341
代理机构 代理人
主权项
地址